Back to search

Article

The Spectrum of Venetoclax-Based Treatments in Acute Myeloid Leukemia

2026-03-23

Abstract excerpt

<h4>Background: </h4> /Objectives: In the recent years there has been a consistent development of clinical studies surrounding the incorporation of the B-cell lymphoma 2 (BCL-2) inhibitor Venetoclax (VEN) into the treatment of acute myeloid leukemia (AML). <h4>Methods:</h4> A search of literature showed a tremendous development of experimental and clinical studies evaluating the impact of VEN-based regimens in the...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
861efc95-6e25-5080-a7a6-6db8c8469ccd
DOI
10.20944/preprints202603.1702.v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
The Spectrum of Venetoclax-Based Treatments in Acute Myeloid LeukemiaDOI 10.20944/preprints202603.1702.v1
How we use venetoclax with hypomethylating agents for the treatment of newly diagnosed patients with acute myeloid leukemiaSemantic proximity
Venetoclax in Combination with Hypomethylating Agents for the Treatment of Treatment-Naive B/Myeloid Mixed-Phenotype Acute Leukemia and Relapsed/Refractory Acute Myeloid Leukemia: A Report of 3 Cases.Semantic proximity
Venetoclax in Acute Myeloid Leukemia: Molecular Basis, Evidences for Preclinical and Clinical Efficacy and Strategies to Target ResistanceSemantic proximity
Clinical Experience With Venetoclax in Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia.Semantic proximity
Targeting Acute Myeloid Leukemia with Venetoclax; Biomarkers for Sensitivity and Rationale for Venetoclax-Based Combination TherapiesSemantic proximity
Relapse and resistance in acute myeloid leukemia post venetoclax: improving second lines therapy and combinations.Semantic proximity
Building on Foundations: Venetoclax-Based Combinations in the Treatment of Acute Myeloid LeukemiaSemantic proximity
Single-center retrospective clinical evaluation of venetoclax combined with HMAs and half-dose CAG in the treatment of unfit or refractory/relapsed AMLSemantic proximity
Unraveling Venetoclax Resistance: Navigating the Future of HMA/Venetoclax-Refractory AML in the Molecular EraSemantic proximity
AML under the Scope: Current Strategies and Treatment Involving FLT3 Inhibitors and Venetoclax-Based Regimens.Semantic proximity
Venetoclax-based therapy versus hypomethylating agents alone in unfit patients with newly diagnosed acute myeloid leukemia: a real-world study from the PETHEMA registrySemantic proximity
Reduced Duration and Dosage of Venetoclax Is Efficient in Newly Diagnosed Patients with Acute Myeloid LeukemiaSemantic proximity
Select a neighboring publication to make it the new centre.